Elon Musk's Neuralink said on Monday that it had raised $650 million in its latest funding round as its brain implant device ...

ClearSight, a leading provider of advanced vision correction solutions, is now offering the PanOptix® Trifocal Intraocular ...

In the evolving field of neurodegenerative medicine, the challenge is not merely discovering new treatments but ensuri ...

Neuralink just closed a hefty $650 million Series E round, pushing its valuation past the $9 billion mark. Backed by big names like ARK Invest, Founders Fund, Sequoia Capital, QIA and Valor Equity ...

The company has received FDA Breakthrough Device Designation for its Blindsight vision restoration system and a speech ...

New interoperability advancements in Oracle's enterprise-grade Randomization and Trial Supply Management (RTSM) solution are helping simplify and optimize drug supply management across complex ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Neuralink closed its funding round with participation from key investors including ARK Invest, DFJ Growth, Founders Fund, G42 ...

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good ...

Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been ...

Elon Musk's Neuralink said on Monday that it had raised $650 million in its latest funding round as its brain implant device ...